October 24, 2025 12:00 ET | Source: Flare Therapeutics Inc. FX-909, the first small molecule targeting PPARG to be tested…
AUSTIN, Texas, Oct. 23, 2025 (GLOBE NEWSWIRE) -- The award-winning film An Inconvenient Study has been seen by millions following its…
SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading…
Completed Enrollment in First-In-Human Phase I study of Less Invasive Approach Expected to Present 6-Month data in 2026 at a…
Up to 7,800 whole genomes and epigenomes to be sequenced on PacBio’s Revio system, powering one of the largest studies…
BERLIN, Oct. 7, 2025 /PRNewswire/ -- New research presented today at UEG Week 2025 shows that microplastics – plastic particles smaller…
19th year of survey reveals cybersecurity remains top concern as workforce-related risks fall on global risk agenda DUBLIN, Oct. 1,…
New findings reveal critical microbial drivers, ethnic variations, and new pathways for personalized scalp care NEW YORK, Sept. 29, 2025…
Company maintains confidence in ReNu as innovative pain management therapy Second Phase 3 trial demonstrates numerical improvement in baseline pain…
DXC is ranked a leader across all categories in the US, AP&J, and Europe. ISG highlighted DXC's leadership through its…